33.58USD-1.67%Mkt Cap: 6.94B USDP/E: —Last update: 2026-05-26
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap6.94B USD
Enterprise Value6.11B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-505.61M USD
Revenue/Share—
Last Price33.58 USD
Fiscal Year EndMar 2026
MR QuarterMar 2026
Employees315
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-14.24
PEG—
EV/EBITDA-11.46
EV/Revenue—
P/S—
P/B7.04
EPS (TTM)-2.77
EPS (Forward)-2.40
52W Range
13.7988% of range36.28
52W High36.28 USD
52W Low13.79 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-59.30%
ROA-52.83%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-407.31M USD
CapEx (TTM)8.00K USD
FCF Margin—
FCF Yield-3.38%
Net Debt-902.04M USD
Net Debt/EBITDA1.69
Balance Sheet
Debt/Equity0.00
Current Ratio9.09
Quick Ratio8.68
Book Value/Sh4.850 USD
Cash/Share4.394 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Target (Mean)41.29 USD
Target Range22.00 USD – 66.00 USD
# Analysts17
Ownership
Shares Out.205.31M
Float77.72M
Insiders56.76%
Institutions54.75%
Short Interest
Short Ratio11.5d
Short % Float20.89%
Short % Out.9.13%
Shares Short18.59M
Short (prev mo.)18.43M
Technical
SMA 5026.74 (+25.6%)
SMA 20023.05 (+45.7%)
Beta0.70
S&P 52W Chg28.31%
Avg Vol (30d)2.24M
Avg Vol (10d)3.53M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—